LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
Ziyi He, Wei Feng, Yuxuan Wang, Liang Shi, Yuhui Gong, Yichao Shi, Shiyu Shen, Haitao Huang
Abstract
Background: mutation and its association with the tumor immune microenvironment (TIME) and immunotherapy. Methods: wild-type groups. Additionally, we performed multiplex immunohistochemistry (mIHC) to validate the differences in the tumor microenvironment. Results: -mutated LUAD patients showed a significant prolongation of progression-free survival (PFS) in the ICIs cohort and could be effectively predicted by our constructed nomogram. Conclusions: mutation is associated with higher immune cell infiltration and elevated immune gene expression in TIME and potentially serves as a prognostic biomarker for LUAD patients treated with ICIs.
Topics & Concepts
ImmunotherapyImmune systemMedicineImmune checkpointCancer researchTumor microenvironmentAdenocarcinomaImmunologyCancerInternal medicineFerroptosis and cancer prognosisCancer Immunotherapy and BiomarkersLymphoma Diagnosis and Treatment